ANAPTYSBIO, INC

Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.

ANAB | NDAQ

Overview

Corporate Details

ISIN(s):: US0327241065
LEI:
Country:: United States of America
Address:: 10770 WATERIDGE CIRCLE, SUITE 210, 92121 SAN DIEGO
Website:: https://www.anaptysbio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnaptysBio, Inc. is a clinical-stage biotechnology company that develops innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes rosnilimab, a pathogenic T cell depleter in Phase 2b trials for rheumatoid arthritis, and ANB033, a CD122 antagonist. AnaptysBio has announced plans to separate its biopharmaceutical operations from its royalty assets into two independent, publicly traded companies by year-end 2026 to align with different investor strategies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ANAPTYSBIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ANAPTYSBIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ANAPTYSBIO, INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Entrada Therapeutics, Inc. Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.	United States of America	TRDA
ENZYCHEM LIFESCIENCES CORPORATION Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.	South Korea	183490
Enzymatica AB Develops medical devices with patented enzyme technology to treat upper respiratory infections.	Sweden	ENZY
Epi Biotech Co., Ltd. Developing alopecia therapies, skin regeneration products, and preclinical CRO services.	South Korea	446440
EQL Pharma AB Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.	Sweden	EQL
Equillium, Inc. Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.	United States of America	EQ
Erasca, Inc. Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.	United States of America	ERAS
Ernexa Therapeutics Inc. Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.	United States of America	ERNA
ERYTECH Pharma S.A. Developing phage therapies to combat antibiotic-resistant bacterial infections.	France	ERYP
Esperion Therapeutics, Inc. Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.	United States of America	ESPR